| Literature DB >> 30034623 |
Ewelina Węglarz-Tomczak1,2, Michał Talma1, Mirosław Giurg3, Hans V Westerhoff2, Robert Janowski4, Artur Mucha1.
Abstract
The potent transcription inhibitor Actinomycin D is used with severalEntities:
Keywords: actinomycin D; biological activity; cancer; metalloaminopeptidases; phenoxazones
Year: 2018 PMID: 30034623 PMCID: PMC6047675 DOI: 10.18632/oncotarget.25532
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Structures of Actinomycin D, Actinomycin X2, Actinocin and Questiomycin A
Inhibitory activities of Actinomycin D and its analogs Actinomycin X2, Actinocin and Questiomycin A toward two human neutral aminopeptidases (HsAPN and HsMetAP)
| Compound | ||||
|---|---|---|---|---|
| Actinomycin D | 11.9 ± 1.1 | 7.37 ± 0.56 | ||
| Actinomycin X2 | 12.2 ± 1.4 | 8.33 ± 0.75 | ||
| Actinocin | 6.04 ± 0.51 | 7.25 ± 1.2 | 2.04 ± 0.23 | 2.34 ± 0.62 |
| Questiomycin A | 52.5 ± 2.7 | 63.0 ± 3.2 | 30.4 ± 3.2 | 34.9 ± 3.2 |
The inhibitors were screened in TRIS buffer. The release of the fluorophore was monitored continuously. The linear portion of the progress curve was used to calculate the velocity. Each experiment was repeated at least three times and the results are presented as the average with standard deviation. For more details, please see the Materials and methods section.
*Calculated based on the Cheng-Prusoff equations for non-competitive and competitive inhibitors [66].
Figure 2Progress curves for the hydrolysis of Ala-AMC by HsAPN in the presence of increasing concentrations of (A) Actinomycin D and (C) Actinocin. The final concentrations of Ala-AMC and HsAPN were 50 μM and 1 nM, respectively. Dixon plots of the inhibition of HsAPN by (B) Actinomycin D and (D) Actinocin in the presence of substrate and inhibitor at different concentrations.
Figure 3Modeled mode of binding for Actinomycin D and Actinomycin X2 to human alanine aminopeptidase (pdb code: 4FYT) [76]
(A and B) The overall views. (C and D) Interactions with the amino acid residues in the inner cavity. Inhibitor and enzyme amino acid residues are shown as sticks, with yellow for the inhibitor. The catalytic zinc ion is shown as a dark blue sphere. The enzyme surface is colored according to the character of the hydrogen bonds formed.
Figure 4Modeled mode of binding for Actinomycin D and Actinomycin X2 to human methionine aminopeptidase (pdb code: 5D6E) [77]
(A and B) The overall view. (C and D) Interactions with the amino acid residues at the entrance to the active site. Inhibitor and enzyme amino acid residues are shown as sticks, with yellow for the inhibitor. The cobalt ions are shown as dark purple spheres. Ligand interactions are shown as green lines.
Figure 5Modeled modes of binding for Actinocin to human alanine aminopeptidase
(A) Interaction of the carbonyl oxygen with the zinc ion. (B) Interaction of the carboxyl group with the zinc ion. Inhibitor and enzyme amino acid residues are shown as sticks. The catalytic zinc ion is shown as a dark blue sphere. Hydrogen bonds, interactions with metal ions and hydrophobic contacts are shown as green lines.
Figure 6Modeled mode of binding for Actinocin to human methionine aminopeptidase 2
Inhibitor and enzyme amino acid residues are shown as sticks. Cobalt ions are shown as dark purple spheres. Hydrogen bonds, interactions with metal ions and hydrophobic contacts are shown as green lines.
Figure 7Modeled modes of binding for Questiomycin A to (A) human alanine aminopeptidase and (B) methionine aminopeptidase 2. Inhibitor and enzyme amino acid residues are shown as sticks. The catalytic zinc ion is shown as a dark blue sphere. Hydrogen bonds and hydrophobic contacts are shown as green lines.